•  
  •  
 

Abstract

Vaksin COVID-19 terbilang efektif untuk mengendalikan pandemi, namun pemberian vaksinasi belum tentu dapat 100% menjamin seseorang terhindar dari COVID-19, vaksin COVID-19 bisa mencegah dari tingkat keparahan COVID-19. Tujuan penelitian ini untuk melihat besaran risiko faktor prediktor yang mempengaruhi derajat keparahan COVID-19. Penelitian ini menggunakan desain studi crossectional dengan purposive sam pling. Sampel berjumlah 1530 responden, diambil dari seluruh kasus positif COVID-19 yang berada di 4 puskesmas di Kabupaten Bandung pada Desember 2021 hingga Mei 2022 dan memiliki ketersediaan data lengkap. Data dianalisis dengan menggunakan software analisis dengan Regresi Logistik. Hasil penelitian didapatkan bahwa odds responden yang belum mendapat vaksin sebesar 2,8 kali untuk mengalami tingkat keparahan COVID-19 dibandingkan subjek penelitian yang sudah booster. Jenis vaksin AstraZeneca 1,8 kali mengalami tingkat keparahan COVID-19 dibandingkan vaksin Pfizer. Vaksinasi terbukti dapat mencegah keparahan COVID-19 namun tidak dapat mencegah tertular COVID-19.

References

  1. Kemkes RI. Antisipasi Gelombang Ketiga, Kenali Ciri dan Cara Mencegah Penularan Omicron. https:// www.kemkes.go.id/article/view/22012700001/antisipasi gelombang-ketiga-kenali-ciri-dan-cara-mencegah-penularan omicron.html (2022).
  2. RI, K. Kasus Pertama Omicron di Indonesia. Kasus Omicron Pertama di Indonesia https://sehatnegeriku.kemkes.go.id/ baca/rilis-media/20211219/5339013/kasus-pertama omicron-di-indonesia-diduga-dari-wni-yang-datang-dari nigeria/.
  3. Burhan, E. et al. Pedoman Tatalaksana COVID-19 Edisi 4 Januari 2022. Pedoman tatalaksana COVID-19 edisi 4 (2022).
  4. RI, D. J. P. K. K. Dukungan RSJPDHK dalam Pelaksanaan Vaksinasi Di Istana Negara. https://yankes.kemkes.go.id/ read/207/dukungan-rsjpdhk-dalam-pelaksanaan-vaksinasi di-istana-negara.
  5. Kemkes RI. Vaksinasi COVID-19 untuk Anak Usia 6-11 Tahun dimulai 14 Desember. https://www.kemkes.go.id/ article/view/21121300001/vaksinasi-covid-19-untuk anak-usia-6-11-tahun-dimulai-14-desember.html.
  6. COVID-19.go.id. Vaksin COVID-19 Moderna Diprioritaskan Jadi Dosis Ketiga (Booster) untuk Tenaga Kesehatan. https:/ /covid19.go.id/edukasi/masyarakat-umum/vaksin-covid 19-moderna-diprioritaskan-jadi-dosis-ketiga-booster-untuk tenaga-kesehatan.
  7. COVID-19.go.id. Situasi COVID-19 di Indonesia Update 17 Februari 2022. https://covid19.go.id/artikel/2022/02/17/ situasi-covid-19-di-indonesia-update-17-februari-2022.
  8. Pikobar. Kasus konfirmasi Jawa Barat per 17 Februari 2022. https://pikobar.jabarprov.go.id/distribution-case.
  9. www.covid-19.go.id. Peta Sebaran COVID-19. https:// covid19.go.id/peta-sebaran# (2022).
  10. CDC. COVID-19 Vaccine Breakthrough Infections Reported to CDC —. MMWR. Morb. Mortal. Wkly. Rep. 70, 792–793 (2021).
  11. Erawan, M. A. S. P., Zaid, Z., Pratondo, K. & Lestari, A. Y. Predicting Covid-19 Vaccination Intention: The Role of Health Belief Model of Muslim Societies in Yogyakarta. Al-Sihah Public Heal. Sci. J. 13, 36 (2021).
  12. Kemkes RI. Jumlah Pasien COVID-19 di Rumah Sakit Rendah Walau Konfirmasi Kasus Harian Tinggi. https:// www.kemkes.go.id/article/view/22020500001/jumlah pasien-covid-19-di-rumah-sakit-rendah-walau-konfirmasi kasus-harian-tinggi.html (2022).
  13. Kemkominfo. 4 Upaya untuk Wujudkan Target Indonesia Dari Pandemi Menuju Endemi. https://covid19.go.id/ edukasi/masyarakat-umum/4-upaya-untuk-wujudkan target-indonesia-dari-pandemi-menuju-endemi (2021).
  14. www.covid19.who.int. Dashboard COVID-19 in Malaysia. https://covid19.who.int/region/wpro/country/my (2022).
  15. www.covid19.who.int. Dashboard COVID-19 in Vietnam. https://covid19.who.int/region/wpro/country/vn (2022).
  16. www.covid19.who.int. Dashboard COVID-19 in Thailand. https://covid19.who.int/region/searo/country/th (2022).
  17. Kumar, S., Thambiraja, T. S., Karuppanan, K. & Subramaniam, G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J. Med. Virol. 94, 1641–1649 (2022).
  18. Saxena, S. K. et al. Characterization of the novel SARS-CoV 2 Omicron (B.1.1.529) variant of concern and its global perspective. J. Med. Virol. 94, 1738–1744 (2022).
  19. Kong, H. & Services, H. COVID-19. 2–7 (2021).
  20. Poudel, S. et al. Highly mutated omicron variant sparks significant concern among global experts – What is known so far? Travel Med. Infect. Dis. 45, (2022)
  21. Kim, H., Webster, R. G. & Webby, R. J. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol. 31, 174–183 (2018).
  22. Juthani, P. V. et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect. Dis. 21, 1485–1486 (2021).
  23. Pollett, S. D. et al. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity. Clin. Infect. Dis. 74, 897–900 (2022).
  24. Dagan, N. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 384, 1412–1423 (2021).
  25. Bhandari, S. et al. Patient Flow Dynamics in Hospital Systems During Times of COVID-19: Cox Proportional Hazard Regression Analysis. Front. Public Heal. 8, 1–7 (2020).
  26. Bernal, J. L. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv 2021.03.01.21252652 (2021).
  27. Bergwerk, M. et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N. Engl. J. Med. 385, 1474 1484 (2021).
  28. Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416 (2021).
  29. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
  30. Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646–1657 (2021).
  31. Novita Putri Evayanti, S. W. U. Tingkat Keparahan Infeksi Terobosan SARS-COV-2 Setelah Vaksinasi COVID-19: Tinjauan Literatur. J. Med. Hutama 3, 58–66 (2022).

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.